Matt Galsky continues his discussion on ctDNA in bladder cancer and covers topics such as candidate versus panel approaches. Dr. James Catto joins the podcast to compare robotic cystectomy against open cystectomy for patients with bladder cancer. Ananya Choudhury explains trimodality therapy for bladder cancer and myths around trimodal therapy and radical cystectomy. Matt Galsky, MD, talks about his new ctDNA study as well as how ctDNA may play a role in upcoming neoadjuvant trials. Yohann Loriot, MD, PhD, discusses the practice-changing THOR study data on the benefit of erdafitinib for advanced UC. Shilpa Gupta, MD discusses two oral abstracts from ASCO 2023 on the CONTACT-03 trial and the EV-103 trial. Dr. Meeks discusses expression-based subtypes for defining pathologic response to neoadjuvant ICIs in patients with MIBC. Sia Daneshmand, MD, reviews 2 studies on the use of erdafitinib for the treatment of NMIBC, including the THOR-2 trial. The Uromigos are joined by Kala Sridhar, MD, to discuss the PET MUSE study on the impact of PET imaging in MIUC. Michiel Van der Heijden, MD, PhD, joined The Uromigos to review bladder cancer research from the 2023 ASCO GU Symposium. Matt Galsky, MD discusses updates for the CheckMate 274 Trial at the 2023 ASCO GU Cancers Symposium with The Uromigos. Enrique Grande, MD, PhD, Msc, met with The Uromigos at the 2023 ASCO GU Cancers Symposium to discuss the IMvigor130 study. Andrea Necchi, MD describes the results of the phase 2 KEYNOTE-057 study at the 2023 ASCO GU Cancers Symposium. Vadim Koshkin, MD, discusses the prevalence of HER2 expression in bladder cancer and the UNITE study for advanced UC. Petros Grivas, MD, PhD, joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer. A summary of the prostate and bladder cancer session of the Conversations & Trending Topics in GU Cancers conference. Sam Chang, MD, MBA, joins The Uromigos to discuss the results of IL-15RαFc superagonist N-803 for papillary NMIBC. Is cisplatin any different from carboplatin in advanced bladder cancer? The Uromigos debate the topic with Matt Galsky, MD. Dr. Andrea Necchi describes his recent phase 2 study on the use of neoadjuvant pembrolizumab and nab-paclitaxel for MIBC. The Uromigos chat with Cora Sternberg on her paper on FGFR inhibition in advanced urothelial cancer.